Testing chemotherapy with bevacizumab to make liver-only colorectal cancer removable
Tests FOLFOXIRI with bevacizumab in adults with colorectal cancer spread only to the liver.
Key facts
- Who runs it
- University of Saskatchewan
- Where
- Regina, CanadaSee the site
- Trial code
- Registry title
- Conversion From Unresectable To Resectable Metastatic Colorectal Cancer.
- Status
- Recruiting
- Phase
- Phase 2
- People taking part
- 32 people, planned
- Started
- 1 May 2025
- Expected to end
- 31 Dec 2026
- Type of study
- Interventional
- Treatments tested
- FOLFOXIRI and Bevacizumab
- Record updated
- 9 May 2025
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with colon or rectal cancer that has spread only to the liver and cannot be removed by surgery. It tests chemotherapy with bevacizumab to see if the liver spread can become removable.
- Age
- 18 to 70 years
- Sex
- Men and women can join.
- Disease stage
- Colon or rectal cancer (adenocarcinoma or poorly differentiated carcinoma) with liver-only metastases that cannot be removed by surgery, and no cancer outside the liver.
- Earlier treatment
- No previous chemotherapy for advanced disease.
Main reasons for not taking part
- Breastfeeding or pregnancy
- An active second primary cancer (skin squamous cell carcinoma or in situ cancer is allowed)
- Severe or uncompensated other medical conditions
- Cancer spread outside the liver
- Poorly working bone marrow, liver or kidneys
The registry criteria, word for word
Show all 7 criteriaShow less
Who can take part
- Adult patients, aged between 18 and 70 years with histologically proven adenocarcinoma or poorly differentiated carcinoma of the colon and rectum with unresectable liver-only metastases and no extra-hepatic disease
- World Health Organization (WHO) performance status of 0-1
- No previous chemotherapy for advanced disease
- Adequate functioning of the bone marrow, liver, and kidneys
Who cannot take part
- Severe or uncompensated concomitant medical conditions
- An active second primary cancer with the exception of squamous cell carcinoma of the skin or an in situ cancer
- Breastfeeding or pregnancy
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 70 years old?
Where in Canada
- Allan Balir Cancer CenterRegina, CanadaContact: Haji Chalchal, MDTaking people
About the trial
What the trial wants to find out
Most patients with mCRC are treated with palliative chemotherapy and only a small number of patients with limited metastatic disease achieve long-term remission following metastasectomy. There is a growing need for more effective treatment in patients with liver-only mCRC to improve the rate of curative resection without compromising QOL.The current study is informed by our patient's needs. It aims to evaluate the rate of conversion therapy in patients with unresectable liver-only mCRC using the combination of FOLFOXIRI and bevacizumab and to assess the association between an early FDG-PT/CT response and other clinical and pathological biomarkers and hepatic metastasectomy.
The group in the trial
- Single armOther group
FOLFOXIRI and Bevacizumab
Treatment: FOLFOXIRI and Bevacizumab
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Conversion From Unresectable To Resectable Liver Metastases In Patients With Liver-Only Metastatic Colorectal Cancer Treated With FOLFOXIRI Plus Bevacizumab. The Conversion Trial.
- Plain-language title
- Testing chemotherapy with bevacizumab to make liver-only colorectal cancer removableGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Fit questions
- Built from NCT03401294, who can take part
- Record updated
- 9 May 2025